Overall treatment plan, including both the in vivo purging phase (cyclophosphamide and cytarabine) and subsequent myeloablative antilymphoma therapy (melphalan and mitoxantrone plus melphalan).

The doses were as follows: cyclophosphamide, 7 g/m² of body-surface area; cytarabine, 1.5 to 2 g/m² every 12 hours for 6 consecutive days; recombinant granulocyte colony-stimulating factor (CSF) or recombinant granulocyte-macrophage CSF, 5 μg/kg of body weight/day; reinfusion 1, 2 × 10⁶CD34⁺ cells/kg, irrespective of polymerase chain reaction (PCR) status; and reinfusions 2 and 3, 5 × 10⁶ and at least 8 × 10⁶ CD34⁺ cells/kg, respectively, only if PCR negative. Intervals between cycles are approximate.